TUMOR-ASSOCIATED ADIPOCYTES, REDOX STATE OF ADIPOSE TISSUE AND MICROMETASTASIS IN GASTRIC CANCER PATIENTS

Authors

  • I.I. Ganusevich R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
  • A.P. Burlaka R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
  • A.V. Vovk R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.32471/oncology.2663-7928.t-21-3-2019-g.7664

Keywords:

gastric cancer, general survival, metastasis, minimal residual disease, superoxide radicals, tumor-associated adipocytes

Abstract

It is well known that a number of tumors (such as gastric, breast, rectal, ovarian cancers etc.) deve­lop in pla­ces of anatomical accumulation of adipose tissue (AT). The modified redox state of the tumor is a factor that dama­ges the mitochondria of adipocytes and reprogramms them into tumor-associated adipocytes (TAAs) that are characterized by pro-oncogenic properties. TAAs are an important source of adipokines and energy supply for the tumor, so studying the mecha­nisms of cellular and meta­bolic symbiosis of adi­pocytes and tumor cells opens up a new therapeutic and dia­gnostic possibi­lities. In parti­cular, they include prediction of the course of micrometastasis taking into account the amount of TAAs, which will allow to develop an individua­lized antitumor therapy for patients with a minimal residual disease (MRD) and overweight. Objective: to identify interrelations between the amount of TAAs and body mass index (BMI), clini­cal and pathological characteristics, gene­ration rate of superoxide radicals (SR) and the activity of gelatina­ses (matrix metalloproteinases-2 and -9) in tumor associated adipose tissue (TAAT), the amount of disseminated tumor cells (DTCs) in the bone marrow (BM) and life expectancy of patients with gastric cancer (GC). Me­thods: immunocyto- and immunohistochemistry, zimo­graphy, NMR-spectroscopy, statistical analysis (Student’s t-test, Spearman’s rank correlation analysis, Kaplan — Me­ier’s survival analysis). Results: a reliable correlation was found between the amount of TAAs in the tumor and the BMI of the patients with GC (rho = 0.41; p = 0.032). The content of TAAs increases with the growth of tumor size in patients with pT4 category in 1.3 times (p < 0.05), which is higher than in the tumors of patients with pT1. Both regio­nal and remote metastases revealed significantly more TAAs in tumors than in case of the absence of metastases. People with obesity and GC live reliably longer than patients with normal weight. Age of patients affects survival only in the presence of obesity: elderly patients live less than patients of middle age. A large number of TAAs in the tumor are associated, on the one hand, with a high rate of SR generation and activity of gelati­nases in the TAAT, and on the other, with distant metastasis of GC. For patients with M1 category, 83% and 64%, respectively, have higher rates of SR and total activity of gelatinases in TAAT, and a 30% increase in TAAs in the tumor than in patients of the M0 category. For patients without clinically detectable metastases (category M0), a signifi­cantly higher amount of TAAs in the presence of DTC in the BM is characteristic of their absence. Patients with less than 26.5% of TAAs in the tumor live reliably longer and have a 2.9-times lower risk of adverse illness pared to patients whose tumors had TAAs higher than 26.5%. For the group of patients with the existing DTCs in the BM, no reliable dependence of survival on the values of the amount of TAAs (p = 0.6203) was detected, but this dependence was found for patients without micrometastases (p = 0.005). Conclusions: dysfunctional AT is a modi­fier of tumor’s microenvironment and a factor of the formation of its aggressive phenotype. The amount of TAAs is associated with tumor growth, its regional and distant metastasis, deposition of the DTCs in the areas of distant metastasis and can be used to control the formation of MRD and the flow of GC in patients with overweight.

 

References

Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 2013; 1831 (10): 1533–41.

Park J, Morley TS, Kim M, et al. Obesity and cancer — mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 2014; 10: 455–65.

Alexandre L, Long E, Beales IL. Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol 2014; 5 (4): 534–49.

Reaves DK, Ginsburg E, Bang JJ, et al. Persistent organic pollutants & obesity: potential mechanisms for breast cancer promotion. Endocr Relat Cancer 2015; 22 (2): 69–86.

Unger R, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010; 1801: 209–14.

Guh DP, Zhang W, Bansback N, et al. The incidence of comorbidities related to obesity and overweight: A systematic review and meta-analysis. Biomed Central Public Health 2009; 9: 1–20.

Burlaka AP, Sidorik YeP. Radical forms of oxygen and nitric oxide in the tumor process. K: Naukova Dumka, 2006. 227 с.

Shabalina IG, Vrbacký M, Pecinová A, et al. ROS production in brown adipose tissue mitochondria: the question of UCP1-dependence. Biochim Biophys Acta 2014; 1837 (12): 2017–30.

Goossens GH, Blaak EE. Adipose tissue dysfunction and impaired metabolic health in human obesity: a matter of oxygen. Front Endocrinol (Lausanne) 2015; 6 (55): 1–5.

BMI Classification. Global Database on Body Mass Index. World Health Organization 2006; 27: 2012.

Kakeji Y, Maehara Y, Shibahara K, et al. Clinical significance of micrometastasis in bone marrow of patients with gastric cancer and its relation to angiogenesis. Gastr Cancer 1999; 2: 46–51.

De Clerk YA, Perez N, Shimada H, et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52: 701–8.

Burlaka AP, Sidorik EP, Ganusevich II, et al. High formation of superoxide anion and nitric oxide, and matrix metalloproteinases activity in vascular wall of rectal carcinoma vessels. Exp Oncol 2006; 28: 323–5.

Jun DH, Kim BJ, Park JH, et al. Preoperative body mass index may determine the prognosis of advanced gastric cancer. Nutr Cancer 2016; 68 (8): 1295–300.

Lee HH, Park JM, Song KY, et al. Survival impact of postoperative body mass index in gastric cancer patients undergoing gastrectomy. Eur J Cancer 2016; 52: 129–37.

Zhang L, Xu A, Han W, et al. Effect of body mass index on postoperative outcomes in patients with gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2016; 19 (3): 296–9.

Jiang QL, Wang CF, Tian YT, et al. Body mass index does not affect the survival of pancreatic cancer patients. World J Gastroenterol 2017; 23 (34): 6287–93.

Matsunaga T, Saito H, Osaki T, et al. Use of body mass index to predict the prognosis of patients with remnant gastric cancer. Yonago Acta Medica 2017; 60: 126–32.

Wang C, Gao C, Meng K , et al. Human adipocytes stimulate invasion of breast cancer MCF-7 cells by secreting IGFBP-2. PLoSONE 2015; 10 (3): 1–17.

Kamat P, Schweizer R, Kaenel P, et al. Human adipose-derived mesenchymal stromal cells may promote breast cancer progression and metastatic spread. Plast Reconstr Surg 2015; 136: 76–84.

Lee JO, Kim N, Lee HJ, et al. Resistin, a fatderived secretory factor, promotes metastasis of MDA-MB-231 human breast cancer cells through ERM activation. Sci Rep 2016; 6: 18923.

Strong AL, Ohlstein JF, Biagas BA, et al. Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers. Breast Cancer Res 2015; 17: 112.

Published

2019-03-22

How to Cite

Ganusevich , I., Burlaka , A., & Vovk , A. (2019). TUMOR-ASSOCIATED ADIPOCYTES, REDOX STATE OF ADIPOSE TISSUE AND MICROMETASTASIS IN GASTRIC CANCER PATIENTS. Oncology, 21(1), 23–30. https://doi.org/10.32471/oncology.2663-7928.t-21-3-2019-g.7664

Issue

Section

Original investigations